Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.

BACKGROUND α-Fetoprotein (AFP) is used widely as a serological marker for hepatocellular carcinoma. However, the AFP value is elevated in chronic hepatitis C virus (HCV) patients without hepatocellular carcinoma. Yet, data on the impact of direct-acting antiviral agents (DAAs) therapy on AFP levels after viral eradication are still lacking. AIM The aim of this study was to elucidate the changes in the serum AFP level in chronic hepatitis C patients treated with DAA-based therapy and their relation to response and liver fibrosis parameters. PATIENTS AND METHODS A total of 456 chronic HCV patients who received different DAAs-based treatment regimens were enrolled. Laboratory data including serum AFP, transient elastography values, and fibrosis scores were recorded at baseline and sustained virological response at 24 weeks after treatment (SVR24). The outcome was the changes in the AFP level from baseline to SVR24 and its relation to changes in liver fibrosis parameters at SVR24 using Spearman's rank correlation test. RESULTS Overall, 96.9% of enrolled patients were responders. A statistically significant improvement in serum transaminases, albumin, transient elastography values, and fibrosis scores at SVR24 was reported. The AFP level was significantly decreased from a median (interquartile range) of 6 (3.2-10.8) ng/ml before DAAs to 4 (2.3-6) ng/ml at SVR24 (P<0.0001). Only 22.6% of patients showed an increase in the AFP level after treatment. On multivariate analysis, the only independent baseline variable associated with an increase in the AFP level after treatment was baseline AFP (odds ratio: 0.95, 95% confidence interval: 0.91-0.99, P=0.02). There is a significant correlation between changes in AFP and liver fibrosis parameters at SVR24. CONCLUSION DAAs-based regimens are a highly efficient antiviral therapy for chronic hepatitis C patients that resulted in improvements in the serum AFP level.

[1]  T. Huynh,et al.  Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma , 2019, Frontiers of Medicine.

[2]  G. Esmat,et al.  Novel scores combining AFP with non‐invasive markers for prediction of liver fibrosis in chronic hepatitis C patients , 2018, Journal of medical virology.

[3]  Yoshiyuki Suzuki,et al.  Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2 , 2018, Journal of medical virology.

[4]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[5]  G. Esmat,et al.  Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon , 2017, Journal of gastroenterology and hepatology.

[6]  D. Elashoff,et al.  Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals , 2017, Journal of clinical and translational hepatology.

[7]  G. Shiha,et al.  Sofosbuvir‐based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt , 2017, Alimentary pharmacology & therapeutics.

[8]  B. Seifert,et al.  Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[9]  M. Imamura,et al.  Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  K. Hayashi,et al.  α‐fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response , 2016, Journal of gastroenterology and hepatology.

[11]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[12]  H. Wedemeyer.  Towards interferon-free treatment for all HCV genotypes , 2015, The Lancet.

[13]  H. Goto,et al.  Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  G. Dusheiko,et al.  Natural history of hepatitis C. , 2014, Journal of hepatology.

[15]  J. Shim,et al.  Oral antiviral therapy improves the diagnostic accuracy of alpha‐fetoprotein levels in patients with chronic hepatitis B , 2014, Journal of gastroenterology and hepatology.

[16]  Y. Imai,et al.  Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Yee-Kit Tse,et al.  On‐treatment alpha‐fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir , 2014, Hepatology.

[18]  N. Enomoto,et al.  α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C , 2013, Hepatology.

[19]  G. Esmat,et al.  Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup , 2012, Hepatitis monthly.

[20]  H. Marusawa,et al.  Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study , 2012, Journal of Gastroenterology.

[21]  Yoshiyuki Suzuki,et al.  Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy , 2011, Journal of medical virology.

[22]  Yoshiyuki Suzuki,et al.  Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma , 2008, Journal of medical virology.

[23]  B. McMahon,et al.  Clinical significance of elevated alpha‐fetoprotein in Alaskan Native patients with chronic hepatitis C , 2007, Journal of viral hepatitis.

[24]  H. Nomura,et al.  Efficacy of low dose long‐term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha‐fetoprotein: A pilot study , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  M. Tsai,et al.  Predictors of alpha‐fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a–ribavirin combination therapy , 2007, Journal of gastroenterology and hepatology.

[26]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[27]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[28]  N. Lim,et al.  Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma , 2004, American Journal of Gastroenterology.

[29]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[30]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[31]  H. El‐Serag.  Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.

[32]  Takeshi Tokuhisa,et al.  Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation , 2002, The Journal of experimental medicine.

[33]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[34]  K. Migita,et al.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus , 2010, Journal of Gastroenterology.

[35]  PhD Shiro Murashima MD,et al.  A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP , 2006, Digestive Diseases and Sciences.

[36]  M. Sherman.  Hepatocellular carcinoma: epidemiology, risk factors, and screening. , 2005, Seminars in liver disease.

[37]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.